



For Professional Use Only

AmpliSens[®] *Influenza virus A H5N1-FRT*

PCR kit

Instruction Manual

AmpliSens[®]



Ecoli s.r.o., Studenohorska 12
841 03 Bratislava 47
Slovak Republic
Tel.: +421 2 6478 9336
Fax: +421 2 6478 9040



Federal Budget Institute of
Science "Central Research
Institute for Epidemiology"
3A Novogireevskaya Street
Moscow 111123 Russia

TABLE OF CONTENTS

1. INTENDED USE.....	3
2. PRINCIPLE OF PCR DETECTION	3
3. CONTENT.....	3
4. ADDITIONAL REQUIREMENTS	5
5. GENERAL PRECAUTIONS	5
6. SAMPLING AND HANDLING	6
7. WORKING CONDITIONS	9
8. PROTOCOL.....	9
9. DATA ANALYSIS	12
10. TROUBLESHOOTING	14
11. TRANSPORTATION	15
12. STABILITY AND STORAGE	15
13. SPECIFICATIONS	15
14. REFERENCES.....	16
15. QUALITY CONTROL	16
16. KEY TO SYMBOLS USED	17

1. INTENDED USE

AmpliSens[®] Influenza virus A H5N1-FRT PCR kit is an *in vitro* nucleic acid amplification test for qualitative detection of *Influenza virus A* RNA and identifying of H5N1 subtype in the biological material (nasal and oropharyngeal swabs or washes; tracheal aspirate; feces; autopsy material; animal material (bird droppings, cloak, pharyngeal, tracheal swabs, tracheal wash samples, visceral organs from fallen animals) using real-time hybridization-fluorescence detection of amplified products.



The results of PCR analysis are taken into account in complex diagnostics of disease.

2. PRINCIPLE OF PCR DETECTION

Influenza virus A H5N1 detection by the polymerase chain reaction (PCR) is based on the amplification of pathogen genome specific region using specific *Influenza virus A* H5N1 primers. In real-time PCR the amplified product is detected using fluorescent dyes. These dyes are linked to oligonucleotide probes which bind specifically to the amplified product during thermocycling. The real-time monitoring of the fluorescence intensities during the real-time PCR allows the detection of accumulating product without re-opening the reaction tubes after the PCR run.

AmpliSens[®] Influenza virus A H5N1-FRT PCR kit is a qualitative test that contains the Internal Control (Internal Control STI-rec (IC)). It must be used in the extraction procedure in order to control the extraction process of each individual sample and to identify possible reaction inhibition.

AmpliSens[®] Influenza virus A H5N1-FRT PCR kit uses “hot-start”, which greatly reduces the frequency of nonspecifically primed reactions. “Hot-start” is guaranteed by separation of nucleotides and Taq-polymerase by using a wax layer. Wax melts and reaction components mix only at 95 °C. In variant FRT-50 F, “hot-start” is guaranteed by using a chemically modified polymerase (TaqF). The chemically modified polymerase (TaqF) is activated by heating at 95 °C for 15 min.

3. CONTENT

AmpliSens[®] Influenza virus A H5N1-FRT PCR kit is produced in 2 forms:

AmpliSens[®] Influenza virus A H5N1-FRT PCR kit variant FRT **REF** R-V33(RG)-CE.

AmpliSens[®] Influenza virus A H5N1-FRT PCR kit variant FRT-50 F **REF** R-V33(SC)-CE.

AmpliSens® Influenza virus A H5N1-FRT PCR kit variant FRT includes:

Reagent	Description	Volume, ml	Quantity
PCR-mix-1-FEP/FRT Influenza virus A ready-to-use single-dose test tubes (under wax)	colorless clear liquid	0.008	55 tubes of 0.2 ml
PCR-mix-2-FL	colorless clear liquid	0.77	1 tube
Positive Control cDNA Influenza virus A (C+A)	colorless clear liquid	0.1	1 tube
TE-buffer	colorless clear liquid	0.5	1 tube
Negative Control (C-)*	colorless clear liquid	1.6	3 tubes
Internal Control STI-rec (IC)**	colorless clear liquid	0.12	5 tubes

* must be used in the extraction procedure as Negative Control of Extraction.

** add 10 µl of **Internal Control STI-rec (IC)** during the RNA extraction procedure directly to the sample/lysis mixture (see **RIBO-sorb**, **REF** K2-1-Et-50-CE protocol).

Reagents for identifying Influenza virus A subtype H5N1:

Reagent	Description	Volume, ml	Quantity
PCR-mix-1-FEP/FRT Influenza virus A H5N1 ready-to-use single-dose test tubes (under wax)	colorless clear liquid	0.008	55 tubes of 0.2 ml
Positive Control cDNA Influenza virus A H5 (C+H5)	colorless clear liquid	0.1	1 tube
Positive Control cDNA Influenza virus A N1 (C+N1)	colorless clear liquid	0.1	1 tube

AmpliSens® Influenza virus A H5N1-FRT PCR kit variant FRT is intended for 55 reactions (including controls).

AmpliSens® Influenza virus A H5N1-FRT PCR kit variant FRT-50 F includes:

Reagent	Description	Volume, ml	Quantity
PCR-mix-1-FRT (SC) Influenza virus A	colorless clear liquid	0.12	5 tubes
PCR-buffer-Flu	colorless clear liquid	0.28	2 tubes
Polymerase (TaqF)	colorless clear liquid	0.06	1 tube
Positive Control cDNA Influenza virus A (C+A)	colorless clear liquid	0.1	1 tube
TE-buffer	colorless clear liquid	0.5	1 tube
Negative Control (C-)*	colorless clear liquid	1.6	3 tubes
Internal Control STI-rec (IC)**	colorless clear liquid	0.12	5 tubes

* must be used in the extraction procedure as Negative Control of Extraction.

** add 10 µl of **Internal Control STI-rec (IC)** during the RNA extraction procedure directly

to the sample/lysis mixture (see **RIBO-sorb**, **REF** K2-1-Et-50-CE protocol).

Reagents for identifying *Influenza virus A H5N1* subtype:

<i>Reagent</i>	<i>Description</i>	<i>Volume, ml</i>	<i>Quantity</i>
PCR-mix-1-FRT (SC) <i>Influenza virus A H5N1</i>	colorless clear liquid	0.12	5 tubes
Positive Control cDNA <i>Influenza virus A H5 (C_{H5})</i>	colorless clear liquid	0.1	1 tube
Positive Control cDNA <i>Influenza virus A N1 (C_{N1})</i>	colorless clear liquid	0.1	1 tube

AmpliSens[®] *Influenza virus A H5N1*-FRT PCR kit variant FRT-50 F is intended for 55 reactions (including controls).

4. ADDITIONAL REQUIREMENTS

- Transport medium for storage and transportation of respiratory swabs.
- 0.9 % saline solution or phosphate buffer.
- Reagent for pretreatment of viscous fluids (sputum, aspirates).
- RNA/DNA extraction kit.
- Reverse transcription kit.
- Disposable powder-free gloves and a laboratory coat.
- Pipettes (adjustable).
- Sterile RNase-free pipette tips with aerosol filters (up to 200 µl).
- Tube racks.
- Vortex mixer.
- Desktop centrifuge with a rotor for 2-ml reaction tubes.
- PCR box.
- Real-time instruments (for example, Rotor-Gene 3000/6000 (Corbett Research, Australia); iCycler iQ or iCycler iQ5 (Bio-Rad, USA); SmartCycler II (Cepheid, USA).
- Disposable polypropylene microtubes for PCR (0.1- or 0.2-ml; for example, Axygen, USA).
- Refrigerator for 2–8 °C.
- Deep-freezer at the temperature from minus 24 to minus 16 °C.
- Reservoir for used tips.

5. GENERAL PRECAUTIONS

The user should always pay attention to the following:

- Use sterile pipette tips with aerosol filters and use a new tip for every procedure.
- Store all extracted positive material (specimens, controls and amplicons) away from all

other reagents and add it to the reaction mix in a distantly separated facility.

- Thaw all components thoroughly at room temperature before starting an assay.
- When thawed, mix the components and centrifuge briefly.
- Use disposable protective gloves and laboratory cloths, and protect eyes while samples and reagents handling. Thoroughly wash hands afterwards.
- Do not eat, drink, smoke, apply cosmetics, or handle contact lenses in laboratory work areas.
- Do not use a kit after its expiration date.
- Dispose of all specimens and unused reagents in accordance with local regulations.
- Samples should be considered potentially infectious and handled in biological cabinet in compliance with appropriate biosafety practices.
- Clean and disinfect all samples or reagents spills using a disinfectant, such as 0.5 % sodium hypochlorite or another suitable disinfectant.
- Avoid samples and reagents contact with the skin, eyes, and mucous membranes. If these solutions come into contact, rinse the injured area immediately with water and seek medical advice immediately.
- Safety Data Sheets (SDS) are available on request.
- Use of this product should be limited to personnel trained in DNA amplification techniques.
- Workflow in the laboratory must be one-directional, beginning in the Extraction Area and moving to the Amplification and Detection Area. Do not return samples, equipment and reagents in the area where the previous step was performed.



Some components of this kit contain sodium azide as a preservative. Do not use metal tubing for reagent transfer.

6. SAMPLING AND HANDLING



Sampling, transportation and pretreatment of biological and autopsy material must be carried out in strict adherence to the local authorities' requirements regarding to the organization and carrying out of laboratory diagnostics of human diseases caused by highly virulent strains of *Influenza* type A viruses.

AmpliSens[®] Influenza virus A H5N1-FRT PCR kit is intended for analysis of the RNA extracted with RNA extraction kits from the biological material (nasal and oropharyngeal swabs or washes, tracheal aspirate, feces, and autopsy material, animal material (bird droppings, cloak, pharyngeal, tracheal swabs, tracheal wash samples, visceral organs from fallen animals).

6.1 Sampling

Human material:

- *Nasal swab samples* are obtained using sterile dry flocked swabs with plastic shafts for nasopharyngeal swabs. Gently insert the swab along the external nasal wall to a depth of 2–3 cm towards the inferior nasal concha. Then move the swab slightly lower, insert it in the inferior nasal meatus under the inferior nasal concha, rotate, and remove along the external nasal wall.

When the material is obtained, insert the swab into a sterile disposable tube with 500 µl of **Transport Medium for Storage and Transportation of Respiratory Swabs** (REF 959-CE, REF 957-CE, REF 958-CE). Break off the end of shaft to allow tight closing of the tube cap. Close the tube with the solution and the swab.

- *Oropharyngeal swab samples* are obtained using sterile dry rayon swabs with plastic shafts for oropharyngeal swabs. Rotate the swab over the surface of tonsils, palatine arches, and posterior wall of pharynx after gargling the oral cavity with water.

When material is obtained, insert the swab into a sterile disposable tube with 500 µl of **Transport Medium for Storage and Transportation of Respiratory Swabs** (REF 959-CE, REF 957-CE, REF 958-CE). Break off the end of shaft to allow tight closing of tube cap. Close the tube with the solution and the swab.



It is recommended to combine nasal and oropharyngeal swabs in a single tube. For this purpose, place the ends of both shafts into one tube containing 500 µl of **Transport Medium for Storage and Transportation of Respiratory Swabs** (REF 959-CE, REF 957-CE, REF 958-CE) and analyze them as a single sample.

- *Nasal wash.* Patient should sit with head tilted backward. Instill 3-5 ml of warm sterile saline solution into each nostril using disposable probe or syringe. Collect the sample from both nostrils in a single sterile tube using funnel. Only an autoclaved funnel should be used.
- *Oropharyngeal wash.* It is necessary to rinse the mouth with water before sampling. After that rinse the throat thoroughly with 8–10 ml of saline for 10–15 s. Collect the sample to a sterile tube using a funnel. Only an autoclaved funnel should be used.
- *Fecal sample* (1.0 – 3.0 g) should be obtained from a sterile disinfected bedpan or a chamber-pot and transferred to a sterile container with a disposable spatula.
- *Autopsy sample* should be immediately placed in a sterile disposable container and frozen otherwise it should be examined within 1 hour from the time of sample

collection. Store the samples at minus 68 °C for 1 year. Only one freeze-thaw cycle of clinical material is allowed.

Animal material:

Samples obtained from birds

- *Droppings* (4.0 – 5.0 g) are collected to a sterile container.
- *Cloak, pharyngeal, tracheal swabs* are obtained using a sterile dry rayon swabs with plastic shafts. The swab is placed in a sterile disposable tube containing 500 µl of respiratory transport medium, sterile saline or phosphate buffer (137 mM sodium chloride, 2.7 mM potassium chloride, 10 mM sodium monophosphate, 2mM potassium diphosphate; pH 7.5±0.2. Store phosphate buffer at 2–8 °C for 1 year in a tightly sealed polypropylene tube). Break off the end of shaft or cut it off to allow tight closing of the tube cap. Close tube with solution and the swab.
- *Tracheal wash sample* is obtained using a sterile saline.

Samples obtained from other fallen animals

- *Visceral organs (fragments of trachea and lungs)* are collected to sterile disposable containers.

Store the above-mentioned material at 2-8 °C for 1 day before the test or at the temperature below minus 16°C for one week.

6.2 Pretreatment

- *Swabs and washes* are used without pretreatment.
- *Tracheal aspirate*. **Mucolysin** reagent **REF** 180-CE is additionally required. Treat samples according to manufacturer's instructions. The prepared solution (50 µl) is used for RNA extraction. The remaining sample can be frozen for further use.
- *Autopsy material and visceral organs of animals* should be homogenized using a sterile porcelain mortar and pestle. Then prepare the 10 % suspension in sterile saline or phosphate buffer. Transfer the suspension to a 1.5-ml tube and spin at 10,000 rpm for 30 s. Use the supernatant for RNA extraction.
- *Human feces*. Prepare fecal suspension from native feces that were not frozen.

Preparation of 10-20% fecal suspension (can be omitted for watery feces).

Take the required number of 1.5-ml tubes. Pipette 0.8 ml of phosphate buffer of sterile saline into each tube. Transfer 0.1 g (0.1 ml) of fecal sample to the tube using a disposable spatula and stir well on vortex to obtain a homogenous suspension.

If the material cannot be studied within 1 day and/or if continuous storage is required, add glycerol (final concentration, 10–15 %) to 10–20 % fecal suspension. Thoroughly homogenize samples with glycerol, incubate for 30–40 min, and then freeze.

Preparation of clarified fecal extract

Vortex the tubes with the prepared suspension (freshly made or frozen with glycerol) or liquid feces, then centrifuge at 10,000 g (12,000 rpm) for 5 min. Use the supernatant for RNA extraction.

- *Bird droppings.* Use 4.0–5.0 g of droppings for analysis. Prepare a 10 % suspension in sterile saline, thoroughly resuspend, and decant for 10 min. Transfer the supernatant to the tube and centrifuge it at 12,000 rpm for 5 min. Use the supernatant for RNA extraction.

7. WORKING CONDITIONS

AmpliSens® Influenza virus A H5N1-FRT PCR kit should be used at 18–25 °C.

8. PROTOCOL

8.1. RNA extraction

It is recommended to use the following nucleic acid extraction kit:

- RIBO-sorb **REF** K2-1-Et-50-CE.

The DNA extraction of each test sample is carried out in the presence of **Internal Control STI-rec.**

Extract RNA according to the manufacturer's protocol taking into account next additions and improvements:



- Add to each tube **450 µl** of **Lysis Solution**, **10 µl** of **Internal Control STI-rec** and **50 µl** of **Negative Control** reagent.
- The volume of the test sample is **50 µl**.
- Add **50 µl Negative Control (C–) reagent** to the tube labeled **C–** (Negative control of Extraction).
- The volume of RNA-buffer is **40 µl**.

8.2. Reverse transcription

It is recommended to use the following kit for complementary DNA (cDNA) synthesis from RNA.

- REVERTA-L, **REF** K3-4-50-CE.



Carry out the reverse transcription procedure according to the manufacturer's instruction.

8.3. Preparing PCR

The total reaction volume is **25 µl**, the volume of cDNA sample is **10 µl**.

8.3.1 Preparing tubes for PCR

8.3.1.1. Detection of *Influenza virus A* RNA

Variant FRT

1. Prepare the required number of tubes with **PCR-mix-1-FEP/FRT *Influenza virus A*** and wax for amplification of cDNA from clinical and control samples.
2. Add **7 µl** of **PCR-mix-2-FL** to the surface of wax layer into each tube ensuring that it does not fall under the wax and mix with **PCR-mix-1-FEP/FRT *Influenza virus A***.

Variant FRT-50 F

1. Prepare required number of the tubes with **PCR-mix-1-FRT (SC) *Influenza virus A*** (one tube is intended for 11 reactions). Vortex the tube, then centrifuge shortly.
2. For N reactions (including 2 controls), add to a new tube:
10*(N+1) µl of **PCR-mix-1-FRT (SC) *Influenza virus A***,
5.0*(N+1) µl of **PCR-buffer-Flu**, and
0.5*(N+1) µl of **polymerase (TaqF)**.

Vortex the tube, then centrifuge shortly. Transfer **15 µl** of the prepared mixture to each tube.

Steps 3 and 4 are required in both variants.

3. Using tips with aerosol filter, add **10 µl** of **cDNA samples** obtained at the RNA reverse transcription stage.
4. Carry the control amplification reactions:

NCA – Add **10 µl** of **TE-buffer** to the tube labeled NCA (Negative Control of Amplification).

C+A – Add **10 µl** of **Positive Control cDNA *Influenza virus A* (C+A)** to the tube labeled **C+A** (Positive Control of Amplification).

C– – Add **10 µl** of **cDNA samples** obtained by extraction and reverse transcription of the **Negative Control (C–) reagent** to the tube labeled **C–** (Negative control of Extraction).

Step 5 is used only for variant FRT-50 F.

5. Centrifuge the reaction mixture in the Smart Cyclor II minicentrifuge.

8.3.1.2. Identifying *Influenza virus A H5N1* subtype



cDNA samples with positive results after detection of *Influenza virus A* RNA are used for identifying of *Influenza virus A H5N1* subtype.

Variant FRT

1. Prepare the required number of tubes with **PCR-mix-1-FEP/FRT *Influenza virus A H5N1*** and wax for amplification of cDNA from clinical and control samples.
2. Add **7 µl** of **PCR-mix-2-FL** to the surface of the wax layer into each tube, ensuring that it does not fall under the wax and mix with **PCR-mix-1-FEP/FRT *Influenza virus A H5N1***.

Variant FRT-50 F

1. Prepare required number of the tubes with **PCR-mix-1-FRT (SC) *Influenza virus A H5N1*** (one tube is intended for 11 reactions). Vortex the tube, then centrifuge shortly.
2. For N reactions (including 2 controls) add to a new tube:
10*(N+1) µl of **PCR-mix-1-FRT (SC) *Influenza virus A H5N1***,
5.0*(N+1) µl of **PCR-buffer-Flu** and
0.5*(N+1) µl of **polymerase (TaqF)**.

Vortex the tube, then centrifuge it briefly. Transfer **15 µl** of the prepared mixture to each tube.

Steps 3 and 4 are required in both variants.

3. Using tips with aerosol filter, add **10 µl** of **cDNA samples** obtained at the RNA reverse transcription stage.
4. Carry the control amplification reactions:
NCA – Add **10 µl** of **TE-buffer** to the tube labeled NCA (Negative Control of Amplification).
C+_{H5} – Add **10 µl** of **Positive Control cDNA *Influenza virus A H5*** to the tube labeled **C+_{H5}** (Positive Control of Amplification).
C+_{N1} – Add **10 µl** of **Positive Control cDNA *Influenza virus A N1*** to the tube labeled **C+_{N1}** (Positive Control of Amplification).
C– – Add **10 µl** of **cDNA samples** obtained by extraction and reverse transcription of the **Negative Control (C–) reagent** to the tube labeled C– (Negative control of Extraction).

Step 5 is required only for variant FRT-50 F.

5. Centrifuge the reaction mixture in the Smart Cyclor II minicentrifuge.

8.3.2. Amplification

1. Create a temperature profile on your instrument as follows:

Table 3

Amplification program						
Step	Rotor-type instruments ¹			Plate-type instruments ²		
	Temperature, °C	Time	Cycles	Temperature, °C	Time	Cycles
1	95	5 min (variant FRT) or 15 min (variant FRT-50 F)	1	95	5 min (variant FRT) or 15 min (variant FRT-50 F)	1
2	95	10 s	10	95	10 s	10
	54	20 s		54	25 s	
	72	10 s		72	25 s	
3	95	10 s	35	95	10 s	35
	54	20 s Fluorescence acquiring		54	25 s Fluorescence acquiring	
	72	10 s		72	25 s	

Table 4

SmartCycler II instrument amplification program (variant FRT-50 F)

Step	Temperature, °C	Time	Cycles
1	95	900 s	1
2	95	15 s	42
	54	25 s Fluorescence acquiring	
	72	25 s	

Fluorescent signal is detected in the channels for the FAM and JOE fluorophores.

- Adjust the fluorescence channel sensitivity according to the *Important Product Information Bulletin* and Guidelines [1].
- Insert tubes into the reaction module of the device.
- Run the amplification program with fluorescence detection.
- Analyze results after the amplification program is completed.

9. DATA ANALYSIS

Analysis of results is performed by the software of the real-time PCR instrument used by measuring fluorescence signal accumulation in two channels:

In case of detection of Influenza virus A RNA:

- The signal of the *Influenza virus A* cDNA amplification product is detected in the channel for the FAM fluorophore.

¹ For example, Rotor-Gene 3000/6000 (Corbett Research, Australia).

² For example, iCycler iQ, iQ5 (Bio-Rad, USA).

- The signal of the IC cDNA amplification product is detected in the channel for the JOE fluorophore.

In case of identifying of *Influenza virus A H5 N1* subtype:

- The signal of the *Influenza virus A H5* cDNA amplification product is detected in the channel for the FAM fluorophore.
- The signal of the *Influenza virus A N1* cDNA amplification product is detected in the channel for the JOE fluorophore.

Results are interpreted by the crossing (or not-crossing) the fluorescence curve with the threshold line set at the specific level that corresponds to the presence (or absence) of a *Ct* value of the cDNA sample in the corresponding column of the results grid.

Principle of interpretation is the following:

Detection of *Influenza virus A RNA*

1. ***Influenza virus A* cDNA is detected** if the *Ct* value determined in the results grid in the channel for the FAM fluorophore is less than the specified boundary *Ct* value.
2. ***Influenza virus A* cDNA is not detected** in a sample if the *Ct* value is not determined (absent) in the channel for FAM fluorophore or greater than the specified boundary *Ct* value, whereas the *Ct* value determined in the channel for the JOE fluorophore is less than the specified boundary *Ct* value.
3. The result is **invalid** if the *Ct* value is not determined (absent) in the channel for FAM fluorophore, whereas the *Ct* value in the channel for the JOE fluorophore is not determined (absent) or greater than the specified boundary *Ct* value. In such cases, the PCR analysis should be repeated starting from the RNA extraction stage.

Identifying of *Influenza virus A H5N1* subtype

1. *Influenza virus A H5* cDNA is identified in a sample if the *Ct* value determined in the channel for the FAM fluorophore is less than the specified boundary *Ct* value.
2. *Influenza virus A N1* cDNA is identified in a sample if the *Ct* value determined in the channel for the JOE fluorophore is less than the specified boundary *Ct* value
3. The required H5N1 subtype of *Influenza virus* is not identified in a sample if the *Ct* value is not determined (absent) in the channel for the FAM and/or JOE fluorophore, whereas the *Ct* value in the channel for the JOE fluorophore (IC detection) is less than the specified boundary *Ct* value.
4. If the positive signals are determined simultaneously in the sample in the channels for the FAM and JOE fluorophores this indicates that ***Influenza virus A H5N1*** is present in the sample, or several *Influenza virus* subtypes with haemagglutinin 5 and

neuraminidase 1 are present simultaneously.

The result is **equivocal** for the presence of the pathogen or the target gene, if the *Ct* value determined in the channel for detection of the pathogen or the target-gene is less than the specified boundary *Ct* value. In such cases, the PCR should be repeated. If the same result is obtained, the sample is considered positive for this target-gene.



Boundary *Ct* values are specified in the Guidelines [1].

The result of the analysis is considered reliable only if the results obtained for the Positive and Negative Controls of amplification as well as for the Negative Control of extraction are correct (see Tables 5, 6).

Table 5

Results for controls (detection of *Influenza virus* RNA)

Control	Stage for control	Ct value in the channel for fluorophore	
		FAM	JOE
		Pathogen detection	IC detection
C-	DNA/RNA extraction	Absent	<boundary value
NCA	PCR	Absent	Absent
C+A	PCR	<boundary value	Absent

Table 6

Results for controls (identifying of *Influenza virus* A H5N1 subtype)

Control	Stage for control	Ct value in the channel for fluorophore	
		FAM	JOE
		H5 target-gene detection	N1 target-gene detection
C-	DNA/RNA extraction	Absent	Absent
NCA	PCR	Absent	Absent
C+ _{H5}	PCR	<boundary value	Absent
C+ _{N1}	PCR	Absent	<boundary value

10. TROUBLESHOOTING

Results of analysis are not taken into account in the following cases:

1. The *Ct* value determined for the Positive Control of amplification (C+) in the channels for the respective fluorophores is greater than the boundary *Ct* value or absent. The amplification should be repeated for all the samples in which the specific RNA was not detected.
2. The *Ct* value determined for the Negative Control of Extraction (C-) and/or Negative Control of Amplification (NCA) in the channel for the pathogen detection is less than the specified boundary *Ct* value. The PCR analysis (beginning with the RNA extraction stage) should be repeated for all samples in which specific RNA was detected to exclude the probable contamination.

If you have any further questions or if encounter problems, please contact our Authorized representative in the European Community.

11. TRANSPORTATION

AmpliSens® Influenza virus A H5N1-FRT PCR kit should be transported at 2–8 °C for no longer than 5 days.

12. STABILITY AND STORAGE

All components of the **AmpliSens® Influenza virus A H5N1-FRT** PCR kit are to be stored at 2–8 °C when not in use (except for Polymerase(TaqF), PCR-mix-1-FRT (SC) *Influenza virus A* and PCR-mix-1-FRT (SC) *Influenza virus A H5N1*). All components of the **AmpliSens® Influenza virus A H5N1-FRT** PCR kit are stable until the expiry date stated on the label. The shelf life of reagents before and after the first use is the same, unless otherwise stated.



Polymerase (TaqF), PCR-mix-1-FRT (SC) *Influenza virus A*, and PCR-mix-1-FRT (SC) *Influenza virus A H5N1* are to be stored at the temperature from minus 24 to minus 16 °C



PCR-mix-1-FEP/FRT *Influenza virus A*, PCR-mix-1-FEP/FRT *Influenza virus A H5N1*, PCR-mix-1-FRT (SC) *Influenza virus A*, and PCR-mix-1-FRT (SC) *Influenza virus A H5N1* are to be kept away from light.

13. SPECIFICATIONS

13.1. Sensitivity

Analytical sensitivity of **AmpliSens® Influenza virus A H5N1-FRT** PCR kit is no less than 5×10^3 copies/ml.



The claimed analytical features of **AmpliSens® Influenza virus A H5N1-FRT** PCR kit are guaranteed only when additional reagents kit RIBO-sorb and REVERTA-L (manufactured by Federal Budget Institute of Science “Central Research Institute for Epidemiology”) are used.

13.2. Specificity

The analytical specificity of **AmpliSens® Influenza virus A H5N1-FRT** PCR kit is ensured by the selection of specific primers and probes as well as stringent reaction conditions. The primers and probes have been checked for possible homologies to all sequences published in gene banks by sequence comparison analysis.

The clinical specificity of **AmpliSens® Influenza virus A H5N1-FRT** PCR kit was confirmed in laboratory clinical trials.














14. REFERENCES

1. Guidelines to the **AmpliSens[®] Influenza virus A H5N1-FRT** PCR kit for qualitative detection of *Influenza virus A* RNA and identification of H5N1 subtype in biological material by the polymerase chain reaction (PCR) with real-time hybridization-fluorescence detection developed by Federal Budget Institute of Science “Central Research Institute for Epidemiology”.

15. QUALITY CONTROL

In compliance with Federal Budget Institute of Science “Central Research Institute for Epidemiology” ISO 13485-Certified Quality Management System, each lot of the **AmpliSens[®] Influenza virus A H5N1-FRT** PCR kit has been tested against predetermined specifications to ensure consistent product quality.

16. KEY TO SYMBOLS USED

	Catalogue number		Caution
	Batch code		Sufficient for
	<i>In vitro</i> diagnostic medical device		Expiration Date
	Version		Consult instructions for use
	Temperature limitation		Keep away from sunlight
	Manufacturer	NCA	Negative control of amplification
	Date of manufacture	C-	Negative control of extraction
	Authorized representative in the European Community	C+A, C+H5, C+N1	Positive control of amplification
		IC	Internal control

List of Changes Made in the Instruction Manual

VER	Location of changes	Essence of changes
09.12.10	Cover page	The phrase “For Professional Use Only” was added
	Intended use	The phrase “The results of PCR analysis are taken into account in complex diagnostics of disease” was added
	Content	New sections “Working Conditions” and “Transportation” were added
		The “Explanation of Symbols” section was renamed to “Key to Symbols Used”
	Stability and Storage	The information about the shelf life of reagents before and after the first use was added
		Information that PCR-mix-1-FEP/FRT <i>Influenza virus A</i> , PCR-mix-1-FEP/FRT <i>Influenza virus A H5N1</i> , PCR-mix-1-FRT (SC) <i>Influenza virus A H5N1</i> and PCR-mix-1-FRT (SC) <i>Influenza virus A</i> are kept away from light was added
	Key to Symbols Used	The explanation of symbols was corrected
Amplification	For variant FRT-50 F, 15 min duration was added at the 1 st step of amplification (95 °C)	
Text	The name AmpliSens [®] <i>Influenza virus A H5/N1</i> -FEP was changed to AmpliSens [®] <i>Influenza virus A H5N1</i> -FEP	
27.06.11 RT	Cover page, text	The name of Institute was changed to Federal Budget Institute of Science “Central Research Institute for Epidemiology”
21.09.16 PM	Through the text	Corrections according to the template. The biological material was specified
	8.1. RNA extraction 8.3.2. Amplification 9. Data analysis 10. Troubleshooting	The sections were rewritten
	14. References	The reference to the Guidelines was added
	6. Sampling and handling	In the procedure of nasal swabs sampling the probe with cotton swab was changed to flocked swabs with plastic shafts for nasopharyngeal swabs. In the procedure of human oropharyngeal swabs and bird cloak, pharyngeal, tracheal swabs sampling the probe with cotton swab was changed to rayon swabs with plastic shafts for oropharyngeal swabs
16.03.18 PM	Footer, 3. Content	REF R-V33(iQ)-CE was deleted